INNOVIVA, INC. Increase (Decrease) in Accounts Receivable
INNOVIVA, INC. (INVA) reported Increase (Decrease) in Accounts Receivable of $15.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- INNOVIVA, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $16.82M, a 295.60% increase year-over-year.
- INNOVIVA, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$961.00K.
- INNOVIVA, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $4.80M.
- INNOVIVA, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $9.24M, a 145.54% increase year-over-year.
- INNOVIVA, INC. increase (decrease) in accounts receivable for fiscal 2025 was $14.57M, a 145.44% increase from fiscal 2024.
- INNOVIVA, INC. increase (decrease) in accounts receivable for fiscal 2024 was $5.94M, a 17.51% increase from fiscal 2023.
- INNOVIVA, INC. increase (decrease) in accounts receivable for fiscal 2023 was $5.05M, a 43.35% increase from fiscal 2022.
- INNOVIVA, INC. increase (decrease) in accounts receivable for fiscal 2022 was $3.52M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $15.86M 10-Q · filed 2026-08-05 | $20.66M derived: sum of 3 quarters · filed 2026-08-05 | $29.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$961.00K 10-Q · filed 2026-05-06 | $3.84M derived: sum of 2 quarters · filed 2026-05-06 | $13.08M derived: sum of 3 quarters · filed 2026-05-06 | $17.33M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $14.04M derived: sum of 2 quarters · filed 2026-02-25 | $18.29M derived: sum of 3 quarters · filed 2026-08-05 | $14.57M 10-K · filed 2026-02-25 |
| 2025-09-30 | $9.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $13.49M derived: sum of 2 quarters · filed 2026-08-05 | $9.78M 10-Q · filed 2025-11-05 | -$379.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $533.00K 10-Q · filed 2026-08-05 | -$9.62M derived: sum of 3 quarters · filed 2026-08-05 | -$5.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$3.72M 10-Q · filed 2026-05-06 | -$13.87M derived: sum of 2 quarters · filed 2026-05-06 | -$10.11M derived: sum of 3 quarters · filed 2026-05-06 | $2.53M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$10.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$6.39M derived: sum of 2 quarters · filed 2026-02-25 | $6.25M derived: sum of 3 quarters · filed 2026-02-25 | $5.94M 10-K · filed 2026-02-25 |
| 2024-09-30 | $3.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $16.41M derived: sum of 2 quarters · filed 2025-11-05 | $16.09M 10-Q · filed 2025-11-05 | $19.79M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $12.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $12.33M 10-Q · filed 2025-08-06 | $16.03M derived: sum of 3 quarters · filed 2026-02-25 | $11.51M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | -$315.00K 10-Q · filed 2025-05-07 | $3.39M derived: sum of 2 quarters · filed 2026-02-25 | -$1.14M derived: sum of 3 quarters · filed 2026-02-25 | -$1.35M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$821.00K derived: sum of 2 quarters · filed 2026-02-25 | -$1.04M derived: sum of 3 quarters · filed 2026-02-25 | $5.05M 10-K · filed 2026-02-25 |
| 2023-09-30 | -$4.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$4.74M derived: sum of 2 quarters · filed 2024-11-06 | $1.35M 10-Q · filed 2024-11-06 | $4.01M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | -$215.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $5.87M 10-Q · filed 2024-07-31 | $8.53M derived: sum of 3 quarters · filed 2025-02-26 | $9.40M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $6.09M 10-Q · filed 2024-05-08 | $8.75M derived: sum of 2 quarters · filed 2025-02-26 | $9.61M derived: sum of 3 quarters · filed 2025-02-26 | $9.61M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $3.52M derived: sum of 2 quarters · filed 2025-02-26 | $3.52M derived: sum of 3 quarters · filed 2025-02-26 | $3.52M 10-K · filed 2025-02-26 |
| 2022-09-30 | $867.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $867.00K derived: sum of 2 quarters · filed 2023-11-01 | $867.00K 10-Q · filed 2023-11-01 | $867.00K derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | $0.00 derived: sum of 3 quarters · filed 2024-03-05 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-03-05 | ||
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $0.00 10-K/A · filed 2024-03-05 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 | |||
| 2016-12-31 | $0.00 10-K · filed 2017-02-28 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $0.00 derived: sum of 3 quarters · filed 2017-02-28 | $0.00 10-K · filed 2017-02-28 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $0.00 derived: sum of 2 quarters · filed 2015-11-05 | $0.00 10-Q · filed 2015-11-05 | $0.00 derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $0.00 10-Q · filed 2015-08-06 | $0.00 derived: sum of 3 quarters · filed 2017-02-28 | $0.00 derived: sum of 4 quarters · filed 2017-02-28 |
| 2015-03-31 | $0.00 10-Q · filed 2015-05-08 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | $0.00 derived: sum of 3 quarters · filed 2017-02-28 | -$252.00K derived: sum of 4 quarters · filed 2017-02-28 |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $0.00 derived: sum of 2 quarters · filed 2017-02-28 | -$252.00K derived: sum of 3 quarters · filed 2017-02-28 | -$74.00K 10-K · filed 2017-02-28 |
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$252.00K derived: sum of 2 quarters · filed 2015-11-05 | -$74.00K 10-Q · filed 2015-11-05 | -$776.00K derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-06-30 | -$252.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$74.00K 10-Q · filed 2015-08-06 | -$776.00K derived: sum of 3 quarters · filed 2016-02-24 | -$776.00K derived: sum of 4 quarters · filed 2016-02-24 |
| 2014-03-31 | $178.00K 10-Q · filed 2015-05-08 | -$524.00K derived: sum of 2 quarters · filed 2016-02-24 | -$524.00K derived: sum of 3 quarters · filed 2016-02-24 | -$524.00K derived: sum of 4 quarters · filed 2016-02-24 |
| 2013-12-31 | -$702.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24 | -$702.00K derived: sum of 2 quarters · filed 2016-02-24 | -$702.00K derived: sum of 3 quarters · filed 2016-02-24 | -$702.00K 10-K · filed 2016-02-24 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $0.00 derived: sum of 2 quarters · filed 2014-11-04 | $0.00 10-Q · filed 2014-11-04 | |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $0.00 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | $0.00 10-Q · filed 2014-05-07 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-02-27 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |